UCB lifts 2026 guidance: UCB stock sits 9.50 percent below its 52-week high

Published on 10/23/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB lifts 2026 guidance on October 22, 2026. UCB stock costs EUR 262.00 on October 23, 2026, 9.50 percent below its EUR 289.50 high.

Guidance and valuation context

On October 22, 2026, UCB raised its 2026 revenue and adjusted profit outlook.
Adjusted earnings before interest, taxes, depreciation and amortization growth is projected at 40 to 45 percent.
UCB stock trades at EUR 262.00 at 10:59 a.m. CEST at Lang & Schwarz on October 23, 2026, 9.50 percent below its EUR 289.50 52-week high.
UCB will publish its 2026 annual results on February 25, 2027.

Isometrische 3D-Illustration einer Wertschöpfungskette von Labor über Produktion bis zum Krankenhaus — UCB S.A. mit ISIN BE0003739530 dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) raised its 2026 financial guidance on October 22, 2026, after stronger demand for Bimzelx and continued volume growth from Cimzia. At Lang & Schwarz on October 23, 2026, the stock was EUR 262.00, 9.50 percent below its EUR 289.50 52-week high.

Guidance rises on two medicines

According to MarketScreener on October 22, UCB now expects revenue growth in the low twenties at constant exchange rates, versus its earlier low-to-mid-teens range. The company also lifted its adjusted earnings before interest, taxes, depreciation and amortization growth outlook to the low-to-mid-forties from the mid-teens to low twenties.

The upgrade is driven by Bimzelx performance in the United States, including volume growth, faster patient conversion, higher retention and more favorable net pricing. Cimzia continues to deliver volume growth across markets despite a contracting anti-TNF market, while the updated guidance excludes proceeds from a Priority Review Voucher sale.

What does the upgrade mean for earnings?

The profitability outlook is the sharper change. UCB's adjusted EBITDA growth range of 40 to 45 percent compares with its former 15 to 20 percent range, indicating that management expects sales growth to translate into stronger operating leverage. The company generated revenue of EUR 7.7 billion in fiscal year 2025, providing scale for the 2026 expansion plan, according to Ideal Investor.

February 25, 2027 results date

The next scheduled milestone is UCB's fiscal year 2026 results and formal 2027 guidance on February 25, 2027, a date stated in the company's guidance release carried by MarketScreener. That report should show whether the stronger medicine sales are producing the projected operating leverage.

Stock stays below its yearly high

UCB's market capitalization was EUR 49.6 billion as of October 23, 2026, while its 52-week range was EUR 197.45 to EUR 289.50. The current quote therefore remains 9.50 percent below the top of that range, leaving the guidance upgrade and the February reporting date as the next concrete valuation checkpoints. The further course of trading is shown by the continuously updated real-time quote of UCB stock.